Big Cost Cuts At Dr Reddy’s, US Big Ticket Launch Progress Is Key

Massive reorganization efforts are underway at Dr Reddy’s as it recalibrates costs; an antibiotics site is expected to be sold soon as part of these efforts and more may be in store. Management commentary was, however, upbeat around the growth outlook for the US business, with visibility of 15-20 launches in FY 2019.

Business decision — A MASSIVE REORGANIZATION OF SYSTEMS AND PROCESSES IS UNDERWAY AT DR REDDY'S

Dr. Reddy's Laboratories Ltd. is pushing ahead with sharp cost optimization plans across its operations – manufacturing, R&D and manpower requirements, among other aspects, are all under scrutiny as the firm strives to emerge leaner and more nimble.

“A lot of work has happened around rationalization across the manufacturing network, portfolio, R&D side, manning levels, etc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

16 May 2025

• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

15 May 2025

• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

15 May 2025

• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

15 May 2025

• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.